白细胞介素 6（IL-6）作为髓系来源抑制细胞（MDSC）活性的主要调节因子及癌症免疫治疗的潜在靶点。
IL-6 as a major regulator of MDSC activity and possible target for cancer immunotherapy.
机构信息
Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.
Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg, Germany and Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim, Germany.
出版信息
Cell Immunol. 2021 Jan;359:104254. doi: 10.1016/j.cellimm.2020.104254. Epub 2020 Nov 29.
Myeloid-derived suppressor cells (MDSC) are generated during tumor progression and suppress the anti-tumor functions of T and natural killer (NK) cells. Their enrichment is associated with a bad prognosis and a worse outcome of immunotherapy in cancer patients. The cytokine interleukin (IL)-6 was found to be a crucial regulator of MDSC accumulation and activation as well as a factor, stimulating tumor cell proliferation, survival, invasiveness and metastasis. Accordingly, IL-6 can serve as a negative prognostic marker in cancer. On the other hand, this cytokine is also involved in T cell activation. This review discusses the pleiotropic effects of IL-6 on immune cell populations that are critical for tumor development, such as MDSC and T cells, and summarizes the data on targeting IL-6 or IL-6 receptor (IL-6R) for tumor immunotherapy to block MDSC-mediated immunosuppression in cancer patients.
髓源性抑制细胞 (MDSC) 在肿瘤进展过程中产生，抑制 T 细胞和自然杀伤 (NK) 细胞的抗肿瘤功能。它们的富集与癌症患者预后不良和免疫治疗效果更差有关。细胞因子白细胞介素 (IL)-6 被发现是 MDSC 积累和激活的关键调节剂，也是刺激肿瘤细胞增殖、存活、侵袭和转移的因素。因此，IL-6 可以作为癌症的预后不良标志物。另一方面，这种细胞因子也参与 T 细胞激活。这篇综述讨论了 IL-6 对免疫细胞群体的多效性影响，这些细胞群体对于肿瘤的发展至关重要，如 MDSC 和 T 细胞，并总结了靶向 IL-6 或 IL-6 受体 (IL-6R) 用于肿瘤免疫治疗以阻断癌症患者 MDSC 介导的免疫抑制的相关数据。
Zotero 插件